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A recent major global publication1 has suggested that there is 
a hidden and burgeoning epidemic of cardiovascular disease 
in developing countries. In South Africa a cluster of diseases, 
namely stroke, ischaemic heart disease and hypertensive 
heart disease, account for 4 of the top 10 causes of death, and 
cardiovascular disease accounts for 17% of all deaths.2 In 
developed countries the prevalence of chronic kidney disease 
has shown exponential growth, mainly because of type 2 
diabetes and hypertension.3,4 In South Africa hypertension is 
the dominant risk factor for stroke, coronary heart disease, 
heart failure and chronic kidney disease.1,2
Control of hypertension remains an elusive goal. The 
reasons for this are complex, but doctors’ non-compliance 
with guidelines, patient attitudes and compliance, and poor 
delivery of care at community health centres (CHCs) are 
important factors contributing to poor blood pressure (BP) 
control.  In a previous survey done by Steyn et al.5 in a CHC 
in the Western Cape, 42.1% of patients had a BP below 140/90 
mmHg, patients had little knowledge of their disease, and 
15.5% reported that insufficient medication was provided when 
filling prescriptions.
Objectives 
The objective of the survey was to determine the overall 
quality of hypertensive care and compliance with current 
hypertension guidelines in two CHCs in the Western Cape.
Methods
Two large CHCs predominantly serving black (CHC 1) 
and coloured (CHC 2) patients were selected to participate 
in the survey. A patient questionnaire was designed to 
determine patient demographics, doctors’ compliance with 
hypertension guidelines, factors leading to treatment non-
adherence, and delivery of care. Accuracy of BP reading was 
evaluated by comparing the clinic BP against that measured 
using an approved manometer supervised by a registered 
nurse trained in BP measurement (control BP). Consecutive 
patients attending hypertension clinics at the two CHCs were 
approached to participate in the survey. After giving informed 
consent the patients completed a questionnaire; information 
was verified from the patient notes wherever possible. Weight, 
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Background. Control of hypertension remains an elusive goal, 
but doctors’ non-compliance with guidelines, patient attitudes 
and adherence to treatment, and poor delivery of care at clinics 
are important contributing factors.
Objectives. To determine the overall quality of hypertensive 
care, and compliance with current hypertension guidelines at   
community health centres (CHCs) in the Western Cape.
Methods. Consecutive patients attending hypertension clinics 
at two CHCs were selected to participate. A questionnaire 
was designed to determine patient demographics, doctors’ 
compliance with hypertension guidelines, factors leading to 
treatment non-adherence, and delivery of care. Accuracy of 
blood pressure (BP) recording was evaluated by comparing the 
clinic BP with that measured using an approved manometer.
Results. One hundred and sixty-one patients were evaluated, 
100 from CHC 1 and 61 from CHC 2. There was no difference 
in both control systolic and diastolic BP measured by the 
hypertension nurse (147.9 v. 144.8 mmHg, p = 0.45, and 89.3 v. 
85.6 mmHg, p = 0.14) respectively. All clinic BP readings were 
recorded to the nearest 10 mmHg mercury. The difference in 
both systolic and diastolic BP > 10 mmHg between the clinic 
and control BP was significantly greater at CHC 2 than CHC 1 
(28% v. 56%, p = 0.005, and 43% v. 64%, p = 0.007) respectively. 
Overall, 39.8% of patients had a systolic and diastolic BP < 
140 and < 90 mmHg. The mean number of antihypertensive 
drugs was 2.4 per patient. The use of non-steroidal anti-
inflammatory drugs (NSAIDs) and tricyclic antidepressants 
was high at both centres, and few patients underwent basic 
investigations, lifestyle interventions, risk stratification or 
global cardiovascular risk reduction.
Conclusions.  39.8% of patients achieved a BP < 140/90 
mmHg. There is significant scope for improvement 
in prescription of medication, application of uniform 
lifestyle changes, and avoidance of NSAIDs and tricyclic 
antidepressants. Major deficiencies were identified in BP 
measurement, assessment of target organ damage, risk 
stratification and the reduction of overall cardiovascular risk.
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waist circumference, height, and control BP were measured, 
and body mass index (BMI) was calculated. The study was 
approved by the Western Cape Department of Health and the 
University of Cape Town Research Ethics Committee.  
Normally distributed data were analysed using the Student’s 
t-test, and non-parametric data were analysed using either 
Fisher’s exact test or the chi-square test.
Results
One hundred and sixty-one patients were evaluated, 100 from 
CHC 1 and 61 from CHC 2. The patient demographics are 
shown in Table I. The mean age of the patients was 59 years, 
and 62.1% were female. At both centres the majority of patients 
were pensioners, on disability grants, or unemployed (80.1% in 
total), but this was more marked at CHC 2.  Only the minority 
of patients were employed or studying (19.7%). 
Smoking, alcohol intake and levels of education were 
similar between the centres. The mean BMI was significantly 
higher at CHC 2 than at CHC 1 (33.2 v. 30.7 kg/m2, p < 0.05) 
but waist circumferences were similar (100.6 v. 100.7 cm, p = 
0.96). Overall, 41.9% of men and 85.1% of women had a waist 
circumference above the recommended levels of 102 cm and 
88 cm respectively, and 45.3% of all patients had a BMI greater 
than 30 kg/m2.
Both systolic and diastolic BP measured by the clinic staff 
were significantly higher at CHC 1 than at CHC 2 (152.9 
v. 144.6 mmHg, p = 0.03, and 94.2 v. 89.6 mmHg, p = 0.04) 
respectively. At both centres all clinic BPs were measured 
to the nearest 10 mmHg. There was no difference in both 
control systolic and diastolic BP measured by the hypertension 
nurse (147.9 v. 144.8 mmHg, p = 0.45, and 89.3 v. 85.6 mmHg, 
p = 0.14) respectively. The difference in both systolic and 
diastolic BP > 10 mmHg between the clinic and control BP was 
significantly greater at CHC 2 than CHC 1 (28% v. 56%, p = 
0.005, and 43% v. 64%, p = 0.007) respectively. Overall, 39.8% 
of patients had both a systolic and diastolic BP < 140 and < 90 
mmHg respectively.
Underlying associated diseases and complications of 
hypertension are shown in Table III. There was a significantly 
higher prevalence of ischaemic heart disease at CHC 2 than at 
CHC 1 (21 v. 6%, p = 0.003).
The drug treatment of patients is shown in Table IV. The 
mean number of antihypertensive drugs was 2.4 per patient. 
Table I. Patient demographics
     CHC 1 (SD)  CHC 2 (SD)
Parameter    (N = 100)   (N = 61)  Overall (SD) p-value
Age (years)    57.9 (12.7) 60.8 (7.9)  59 (11.2)  0.1
Males (%)    39  36  37.9  -
Education* (years)    7.6 (2.8)  7.2 (2.7)  7.5 (2.8)  0.32
Any alcohol use (%)   13  10.9  11.8  0.37
Smokers (%)    10  15.1  8.7  0.1
Length of hypertension (years)  7.9 (7.1)  10.8 (9.7)  9 (8.3)  0.03
Weight (kg)    79 (16.3)  80.9 (18.4) 79.7 (17.1) 0.48
Waist circumference (cm)   100.6 (12.5) 100.7 (22.1) 100.6 (16.7) 0.96
Body mass index (kg/m2)   30.7 (7.3)   33.2 (14.2) 31.2 (10.2) 0.05
Employment status (%)    
Pensioner     37  55.7  44.7  0.02
Disability grant    5  13.1  8.1  0.06
Unemployed     33  19.7  28  0.07
Employed     23  11.5  18  0.03
Student     2  0  1.2  0.38
*Number of years in formal education.
SD = standard deviation.
Table II. Mean clinic and control BP, and differences between clinic and control BP
     CHC 1 (SD) CHC 2 (SD) Overall (SD) p-value
Clinic systolic BP (mmHg)   152.9 (24.64) 144.6 (20)  149.7 (23.2) 0.05
Clinic diastolic BP (mmHg)   94.2 (13.9) 89.6 (12.9) 92.4 (13.7) 0.03
Control systolic BP (mmHg)   147.9 (30.1) 144.8 (22.7) 146.7 (27.6) 0.45
Control diastolic BP (mmHg)   89.3 (30.1) 85.6 (12.9) 87.9 (15.7) 0.14
> 10 mmHg difference in systolic BP* (%)  28  56  38.5  0.005
> 10 mmHg difference in diastolic BP* (%) 43  64  50.9  0.007
*Refers to the percentage of patients with more than 10 mmHg difference between the clinic and control BP.
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The median dose (range) of enalapril was 15 mg (5 - 20 mg), 
hydrochlorothiazide 12.5 mg (12.5 - 25 mg), and atenolol 
100 mg (25 - 100 mg). All patients receiving nifedipine GITS 
were prescribed 30 mg. Significant difference in use of 
antihypertensive drugs was revealed between the two centres. 
At CHC 1 patients were more likely to receive a thiazide 
diuretic (88% v. 70.5%, p < 0.006), and less likely to receive a 
beta blocker (38% v. 57.4%, p = 0.02) and a calcium channel 
blocker (CCB) (6% v. 26.2%, p = 0.004). The use of non-steroidal 
anti-inflammatory drugs (NSAIDs), tricyclic antidepressants 
and paracetamol was high at both centres. Patients at CHC 
2 were more likely to receive NSAIDs (42.6% v. 25%, p = 
0.02) than paracetamol (24.6% v. 63%, p = 0.0001). Of the 
patients receiving NSAIDs, 31.9% received ibuprofen, 23.4% 
indomethacin, and 44.7% diclofenac. The overall use of statin 
therapy was very low (2.5%), and low-dose aspirin was more 
likely to be used at CHC 2 (47.5% v. 14%, p = 0.0001).
The performance of routine investigations at both centres 
is shown in Table V. There was a highly significant trend for 
more extensive investigation at CHC 2 than CHC 1 with the 
exception of urinalysis and serum creatinine.
Overall, 61.7% of patients self-reported no missed doses of 
medication and 37.4% admitted missing more than 1 dose of 
medication per week. There was no difference between the 
centres. Fifty-six per cent of patients at CHC 1 reported that 
their prescription was not properly filled at the pharmacy 
in the last year, which was significantly more than at CHC 2 
(21.3%, p = 0.03). 
At CHC 2 56% of patients reported receiving advice on 
lifestyle management of their hypertension, which was 
significantly higher than at CHC 1 (38%, p = 0.03).
Table III. Underlying co-morbid diseases
Co-morbidity   CHC 1 (%) CHC 2 (%) Overall (%) p-value
Cerebrovascular accident      15        15       15     0.98
Ischaemic heart disease        6       21      11.8     0.003
Cardiac failure         8        9       8.1     0.59
Chronic kidney disease        0      1.6       0.6     0.38
Diabetes          8     14.8      10.6     0.4
Asthma          5       11       6.8     0.19
Arthritis        43     47.5           44.7     0.57
Table IV. Percentage of patients treated with each major class of antihypertensive, and other concomitant medication
Medication   CHC 1 (%) CHC 2 (%) Overall (%) p-value
Antihypertensives    
Thiazide diuretics      88      70.5     81.4  < 0.006
ACE inhibitor       61      70.5     64.6  0.22
β-blocker       38      57.4     45.3  0.02
Calcium channel blocker        6      26.2     13.7  0.004
Hydralazine       20      11.5     16.8  0.11
Concomitant medication    
Aspirin       14      47.5     26.7  0.0001
Simvastatin         2        3.4       2.5  0.49
NSAIDs       25      42.6     31.7  0.02
Paracetamol       63      24.6     48.4  0.0001
Tricyclic antidepressants      26      19.7     29.8  0.36
ACE = angiotensin-converting enzyme; NSAIDs = non-steroidal anti-inflammatory drugs.
Table V. Routine investigations performed
Investigation   CHC 1 (%) CHC 2 (%) Overall (%) p-value
Urine dipsticks        44       59      49.7  0.06
Creatinine        17     19.7       18  0.67
ECG           0     27.9      10.6  0.0001
Cholesterol          2     21.3       9.3  0.0001
Glucose         45     70.5       54.7  0.002
ECG = electrocardiogram.
Pg 280-284.indd   282 3/16/07   10:37:11 AM
ORIGINAL ARTICLES
283
April 2007, Vol. 97, No. 4  SAMJ
Discussion
This survey has important implications for the delivery of 
hypertensive care to largely indigent patients in the Western 
Cape. It identifies important deficiencies in administration, 
BP measurement, and compliance with current hypertension 
guidelines. Furthermore it highlights important differences in 
the standard of care within two facilities in close proximity and 
within the same health administration.
The majority of patients attending the CHCs are the 
unemployed, pensioners, and those on disability grants. 
Employed persons and students made up only 19% of those 
surveyed. All patients need to visit the facility monthly, 
and waiting times to see health care personnel and receive 
medication are very long. This appears to be a major 
disincentive to employed people to attend CHCs, and 
administrative processes within these centres need to be 
rationalised to reduce waiting times.  Additionally there is no 
obvious reason why compliant patients with well-controlled 
BP should not be seen 6-monthly, and receive 3 months’ supply 
of medication. Public/private partnerships could also be 
explored.
Another important administrative problem was in the 
delivery of medication to patients. Fifty-six per cent and 26.1% 
of patients at CHCs 1 and 2 respectively reported that their 
scripts for medication were incompletely filled in the last year. 
This is far higher than reported by Steyn et al.5 in the previous 
survey. This certainly will result in increased inconvenience 
and may lead to poorer BP control. The reason for the failure 
to fill prescriptions was not documented, but it was probably 
because of inadequate supplies in the dispensary.
Serious shortcomings in BP measurement were another 
major finding of the survey. In all 161 cases BP was measured 
to the nearest zero, indicating uniform digital bias. This implies 
that BP is only measured to the nearest 10 mmHg, which has 
important implications for assessing control and classifying the 
severity of hypertension. Discrepancies in the BP measured in 
the clinic and control BP were common. For example, 50.9% 
and 38.5% of patients had a difference of more than 10 mmHg 
in diastolic BP and systolic BP respectively. In part, these 
differences may have been due to the reduction in white coat 
effect between the clinic and control BP, but in many cases the 
control BP was higher than the clinic BP and in some cases the 
difference was > 50 mmHg. In addition, this phenomomen was 
more prevalent at CHC 2, suggesting that BP measurement 
was less well performed at this centre, and the significant 
differences in mean systolic and diastolic BP between the 
two centres disappeared once the mean control systolic and 
diastolic BP was used.
Regarding the standard of care of hypertensive patients, 
there were positive aspects to BP control. Overall, 39.8% of 
patients had both a systolic and diastolic BP < 140 and < 90 
mmHg, which is comparable to that reported from other 
centres in the Western Cape. In 1999 Steyn et al.5 reported 
that 42.1% of hypertensives attending CHCs had BP < 140/90 
mmHg, and more recently in a survey6 of black hypertensives 
from peri-urban township areas 33% of men and 44% of 
women had BP < 140/90 mmHg. The control rates were 
not as good as those published by the US National Health 
and Nutrition Examination Survey7 where 53.1% of treated 
hypertensives had BP < 140/90 mmHg. In a survey8 of hospital 
outpatient services in Gauteng only 24.5% of patients had their 
BP controlled. 
With the exception of angiotensin receptor blockers all major 
classes of antihypertensive drugs were available for use by 
health professionals with few restrictions. Thiazide diuretics 
were widely prescribed particularly at CHC 1 in accordance 
with most guidelines. Angiotensin-converting enzyme (ACE) 
inhibitors were the second most popular drug. Beta-blockers 
were more widely used at CHC 2 than at CHC 1, possibly 
because of the higher prevalence of ischaemic heart disease at 
CHC 2 and the reported lesser efficacy of these agents in black 
patients. CCBs were underutilised at both centres, particularly 
at CHC 1. This is an important finding as CCBs are considered 
very effective for treatment of hypertension in black patients,9 
but this may be related to policies of the CHCs where CCBs 
are considered fourth-line therapy because of higher cost of 
these drugs. The monthly cost of amlodipine (the current 
preferred dihydropyridine CCB for the Western Cape) in 
the public sector is R19.14 for 5 mg compared with R0.74 for 
hydrochlorothiazide 12.5 mg daily, R2.36 for atenolol 50 mg 
daily and R2.59 for enalapril 5 mg twice daily.
The use of tricyclic antidepressants (23.6%) and NSAIDs 
(31.7%) in this survey was high despite the known adverse 
effects of these agents on BP, and the potential cardiotoxicity 
of tricyclics. The high use of NSAIDs was probably related to 
the high prevalence of arthritis among the patients. However 
at CHC 1 significantly more patients received paracetamol than 
NSAIDs for analgesia, which again demonstrates the important 
differences in clinical practice between the centres. 
The most serious shortcomings in hypertensive care were 
the inadequate assessment of target organ damage, and 
failure to conduct any form of risk stratification and global 
cardiovascular risk management. Firstly, and not unexpectedly, 
obesity was highly prevalent. Overall, 45.3% of all patients 
were obese with a BMI greater than 30 kg/m2, and 41.9% of 
men and 85.1% of women had a waist circumference above 
the recommended levels of 102 cm and 88 cm respectively. 
Yet only 56% of patients reported ever being counselled on 
improving BP and reducing cardiovascular risk through 
lifestyle measures. As a fasting lipogram and fasting glucose 
test were seldom performed, we were unable to determine the 
prevalence of the metabolic syndrome, but 41.9% of men and 
85.1% of women fulfilled at least two criteria, namely BP and 
waist circumference.
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Secondly, there was no attempt made to undertake 
risk stratification through the performance of a few basic 
investigations. Urinalysis was only performed in 49.7% of 
patients. This was particularly serious at CHC 2, where for 
example none of the 100 patients had an electrocardiogram 
(ECG) performed.  All the investigations shown in Table V 
are mandatory for the proper assessment of a hypertensive 
patient.10 For example, unless a fasting glucose is done 
routinely, the diagnosis of diabetes or impaired fasting glucose 
will be overlooked. The ECG is an important tool for assessing 
left ventricular hypertrophy. Renal disease can be silent, and 
unless routine dipsticks and serum creatinine are performed, 
occult renal disease will be missed. In a recent survey of 
hypertensive patients in the Cape Peninsula,6 silent renal 
disease was present in 25% of men and 6% of women, and 
35% of patients had ECG left ventricular hypertrophy assessed 
using the Sokolow-Lyon criteria. Recognition of target organ 
damage in the early phases of development plays a crucial role 
in risk stratification, choice of antihypertensive therapy and 
intensity of treatment.
Thirdly, the use of statin therapy in this population was 
extremely low. Recent data from the ASCOT Lipid-Lowering 
Arm Trial11 strongly suggests that statin therapy benefits 
patients with hypertension almost regardless of initial 
cholesterol levels. However, in the Western Cape at the time 
of the survey statin therapy was restricted to patients with 
familial hypercholesterolaemia and patients with established 
ischaemic heart disease.  Nonetheless statins were only used 
in 2.5% of patients whereas the prevalence of ischaemic 
heart disease in the survey was 11%, suggesting that the 
restrictive formulary policies were not the sole reason for their 
underutilisation.
The use of aspirin is not well established in hypertensive 
patients. The current hypertension guidelines10 recommend its 
use in high-risk patients provided that BP is well controlled. 
Aspirin was used more often at CHC 2, probably because of 
the higher prevalence of ischaemic heart disease.
Certain weaknesses of the study may have influenced 
results. Firstly, this was a cross-sectional study, and BP control 
was not assessed over time. Furthermore the patients entering 
the study may have been more motivated and/or had more 
time to spend at the clinic, and may therefore have influenced 
the reported level of BP control and the demographics of the 
patients participating.
In conclusion, this survey found that BP control at the two 
CHCs was reasonable compared with other data reported from 
the Western Cape, but not as good as data from the USA. There 
is scope for improvement as many patients were receiving two 
or less antihypertensive drugs and lifestyle measures were not 
uniformly applied.  Additionally, many patients were receiving 
NSAIDs and tricyclic antidepressants that may have worsened 
BP control. There were important administrative deficiencies 
in the delivery of drugs to patients, and long waiting times 
associated with the unemployed, pensioners and those on 
disability grants. There is a large number of employed South 
Africans in low-income groups who do not have medical 
insurance and rely on the public sector for their health care. 
Major deficiencies were identified in BP measurement, 
assessment of target organ damage, risk stratification and the 
reduction of overall cardiovascular risk.
Based on the findings of this survey we recommend the 
following:
1. The health authority needs to familiarise all primary care 
health professionals with the new Hypertension Guidelines10 
formulated by the National Department of Health and the 
South African Hypertension Society, and ensure appropriate 
implementation. Particular attention needs to be paid to 
the importance of measuring BP accurately, implementing 
lifestyle changes, assessing target organ damage with basic 
investigations, risk stratification and global cardiovascular risk 
reduction.
2. Administrative changes need to be made to drastically 
reduce waiting times and ensure smooth supply of medication 
and availability of basic investigations
3. All staff should undergo basic BP training, and reliable 
and durable automated BP manometers should be used in 
clinics.
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